HIV/AIDS Treatment Trends and Progress: Where Do We Stand Today?
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Address: 15e Riley Road
Bedfordview 2008 ,South Africa
Tel: +27 11 087 0000
iNova Pharmaceuticals develops and markets a range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa, the Americas and other international markets.
iNova has a broad range of prescription medicines and consumer healthcare products in several therapy areas including pain management, weight management, allergy, sexual health, dermatology, cardiology and respiratory health.
Among the wide variety of products iNova offers in our commitment to improving people’s health and well being are Australian made and owned market leading brands Difflam™, Duro-Tuss™, Hiprex™, Metsal™ and Cal-Sup™. We are also proud to make available to patients and consumers Azep®, Eyezep®, ZepAllergy™ and Rinar™.
Our broad product range, available in pharmacies only, comes from a heritage of many years of innovation and, more recently, in-licensed products. Strict quality assurance and control procedures help to ensure iNova produces and markets brands meeting the most rigorous quality standards. Our products are prescribed by specialist health care providers and general practitioners across the Region and supported by pharmacy recommendation.
The availability of our marketed products and information we lawfully can provide varies among countries. This website contains information on products which is targeted to a wide range of audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
